Brought to you by 
Abbott acquires Kos for $3.7bn in cash
05 Dec 2006
Executive Summary
Abbott is paying $3.7bn in cash to buy all outstanding common shares of specialty drug company Kos Pharmaceuticals (focusing in the areas of cardiovascular, metabolic, and respiratory diseases) for $78 each, a 58% premium to market.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott acquires Kos for $3.7bn in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice